Invitrogen Ltd
Renfrew UK
Metals, Analytical Chemists, Biotechnology Consultancy, Chemicals...
TEL: 0141-814 6100
FAX: 0141-814 6260
Total : 8 View more »
Renfrew UK
Metals, Analytical Chemists, Biotechnology Consultancy, Chemicals...
TEL: 0141-814 6100
FAX: 0141-814 6260
Total : 2 View more »
Cyclin I is an atypical cyclin because it is most abundant in postmitotic cells. We previously showed that cyclin I does not regulate proliferation, but rather controls survival of podocytes, terminally differentiated epithelial cells that are essential for the structural and functional integrity
Protein S (ProS) is a blood anticoagulant encoded by the Pros1 gene, and ProS deficiencies are associated with venous thrombosis, stroke, and autoimmunity. These associations notwithstanding, the relative risk that reduced ProS expression confers in different disease settings has been
Total : 1 View more »
Sep 25, 2009 (Datamonitor Financial Deals Tracker via COMTEX) --
ArunA Biomedical, Inc. has signed a non-exclusive multi-year distribution agreement with Life Technologies Corporation, a biotechnology tools company, for human embryonic stem cell-derived neural products.
ArunA Biomedical is a biotechnology company. Both ArunA Biomedical and Life Technologies are based in the US.
This agreement includes ArunA's human neural cells that are produced using ArunA's exclusively licensed patented monolayer technology platform. Additional ArunA human cellular products may be added to the agreement in the future.
Deal Type Partnership Sub-Category Distribution Deal Status Announced: 2009-09-24
Deal Participants
Partner 1 (Company) Life Technologies Corporation (formerly Invitrogen Corporation) Partner 2 (Company) Aruna Biomedical, Inc.
Deal Rationale
The agreement will allow Life Technologies to enhance the distribution of stem cell products to the academic and research communities.
Tags: biomedical biotechnology partnership products research technology
Companies: Life Technologies Corp (LIFE)
Total : 486 View more »
DLA Piper advised Invitrogen Corporation in its proposed $6.7 billion merger with Applera Corporation. The deal will create one of the world’s leading biotechnology companies, to be named Applied Biosystems, with expected annual sales of approximately $3.5 billion.
DLA Piper advised Invitrogen Corporation in its proposed $6.7 billion merger with Applera Corporation. The deal will create one of the world’s leading biotechnology companies, to be named Applied Biosystems, with expected annual sales of approximately $3.5 billion. http://www.dlapiper.
Transgenomic Taq DNA polymerase (T-Taq) is a recombinant, thermostable, 94-kDa DNA polymerase encoded in Escherichia coli by a modified form of a DNA polymerase gene from Thermus aquaticus.
Introduction Tyrosine kinases (TKs) are a diverse family of enzymes that under specific signaling conditions phosphorylate proteins on the amino acid tyrosine.
Total : 131,000 View more »
Nucleic Acid Purification & Analysis. Nucleic Acid Purification, Quantitation ... Copyright © 2009 Invitrogen Corporation. All rights reserved.
http://phx.corporate-ir.net/phoenix.zhtml?c=61498&p=irol-newsArticle&ID=1218555&highlight=
FRONTIERS IN BIOSCIENCE; Invitrogen Corporation (Invitrogen) 3985 B Sorrento Valley Blvd. San Diego, CA 92121 _____ Company Phone: (619) 597-6200
A protein engineering company, Avidis offers its affordable High Throughput Robotic Protein Refolding Service and exclusively markets the E. coli strains C41(DE3) and C43(DE3), for overexpressing membrane and toxic proteins.
http://www.smi-online.co.uk/event_media/sponsors.asp?is=4&ref=1351